MEDINET Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on MEDINET's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2018 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MEDINET makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 18 | 998 | -3,048 | 1,529 | 1,502 |
| 30 Jun 18 | 1,160 | -3,797 | 2,521 | 612 |
| 31 Mar 18 | 1,353 | -3,716 | 2,640 | 612 |
| 31 Dec 17 | 1,548 | -3,421 | 2,987 | 612 |
| 30 Sep 17 | 1,704 | -2,603 | 1,955 | 612 |
| 30 Jun 17 | 1,819 | -1,974 | 2,229 | 603 |
| 31 Mar 17 | 1,876 | -1,843 | 2,232 | 603 |
| 31 Dec 16 | 1,895 | -1,580 | 1,988 | 603 |
| 30 Sep 16 | 1,909 | -1,643 | 1,938 | 603 |
| 30 Jun 16 | 1,825 | -1,692 | 1,811 | 645 |
| 31 Mar 16 | 1,737 | -1,865 | 1,791 | 645 |
| 31 Dec 15 | 1,731 | -1,786 | 1,745 | 645 |
| 30 Sep 15 | 1,674 | -1,712 | 1,769 | 645 |
| 30 Jun 15 | 1,679 | -2,051 | 1,615 | 659 |
| 31 Mar 15 | 1,708 | -1,989 | 1,580 | 659 |
| 31 Dec 14 | 1,725 | -1,594 | 1,602 | 659 |
| 30 Sep 14 | 1,843 | -1,580 | 1,573 | 659 |
| 30 Jun 14 | 1,966 | -862 | 1,639 | 518 |
| 31 Mar 14 | 2,083 | -689 | 1,592 | 518 |
| 31 Dec 13 | 2,119 | -489 | 1,519 | 518 |
Quality Earnings: Insufficient data to determine if 2370 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 2370's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2370's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 2370's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if 2370's earnings growth over the past year exceeded the Life Sciences industry average.
Return on Equity
High ROE: 2370 has a negative Return on Equity (0%), as it is currently unprofitable.